<DOC>
	<DOCNO>NCT02905331</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics , immunogenicity , usability , acceptability guselkumab deliver use SelfDose device participant moderate severe plaque-type psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Study Guselkumab Treatment Participants With Moderate Severe Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A woman childbearing potential must negative urine pregnancy test ( betahuman chorionic gonadotropin ) screen Week 0 Before randomization , woman must either : ) Not childbearing potential : premenarchal ; postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 12 month age amenorrhea least 6 month serum folliclestimulating hormone level ( FSH ) &gt; 40 International Units Per Liter [ IU/L ] ) ; permanently sterile ( example , tubal occlusion , hysterectomy , bilateral salpingectomy ) ; otherwise incapable pregnancy , b ) Of childbearing potential practicing highly effective method birth control , consistent local regulation regard use birth control method subject participate clinical study : example , establish use oral , injected implant hormonal method contraception ; placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal foam/gel/ film/cream/suppository ( available locale ) ; male partner sterilization ( vasectomized partner sole partner participant ) ; true abstinence ( line prefer usual lifestyle participant ) Agree receive Bacillus Calmette Guerin ( BCG ) vaccination study , within 12 month last administration study drug Have Psoriasis Area Severity Index ( PASI ) great equal [ &gt; = ] 12 screen baseline Have involve body surface area ( BSA ) &gt; = 10 percent ( % ) screening baseline Has unstable cardiovascular disease , define recent clinical deterioration ( eg , unstable angina , rapid atrial fibrillation ) last 3 month cardiac hospitalization within last 3 month Has history lymphoproliferative disease , include lymphoma ; history monoclonal gammopathy undetermined significance ( MGUS ) ; sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy splenomegaly Has transplant organ ( exception corneal transplant &gt; 3 month first administration study drug ) Has nonplaque form psoriasis ( example , erythrodermic , guttate , pustular ) Has receive antitumor necrosis factor alpha ( TNFalpha ) biologic therapy within 3 month first administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>